COVID-19 therapy and prevention

Since the outbreak of the new coronavirus pneumonia (COVID-19) in December 2019, more than 23 million people worldwide have been diagnosed with SARS-CoV-2. In response to this pandemic, a global mobilization of scientific, industrial and political support has ensued. However, more than 8 months later, as studies multiply and several governments are embarking on a resumption of their activities, the threat still remains. Our efforts to understand the evolution of the virus and the means to defeat it, at the dawn of a possible new wave, have raised more questions than provided clear and unequivocal answers. Compared to diseases caused by previously known human coronavirus, COVID-19 shows higher transmissibility, as a matter of fact "deeply concerning" cases continue to increase. Under these circumstances, and based on the information we have collected so far, this paper provides an overview of the epidemiological status of COVID-19 by considering, first through comparisons with other coronaviruses, similarities that may guide prevention measures and potentially effective therapies. From this starting point, we aimed to discuss the evidence around the efficacy of masks and respirators for different group of the population. Finally, we address therapeutic aspects including perspectives of vaccines and some antimicrobial agents such as remdesivir, favipiravir, chloroquine, hydroxychloroquine in combination with azithromycin and immunomodulators.